Physiological Based Pharmacokinetic Modeling and Simulation (PBPK)

EP-021 - PBPK MODELING OF A NARROW THERAPEUTIC INDEX DRUG AND APPLICATION IN PREDICTING DOSE ESCALATION SCENARIOS, FOOD EFFECT, DDI AND SPECIAL POPULATION.

PT-018 - OPTIMIZATION OF THE BETAMETHASONE DOSING REGIMEN DURING PREGNANCY: A COMBINED PLACENTA PERFUSION AND PREGNANCY PBPK MODELLING APPROACH.

PT-023 - DEVELOPMENT OF INTRANASAL PHYSIOLOGICALLY BASED NOSE TO BRAIN MODEL AND ITS APPLICATION TO CHARACTERIZE IN NEUROEPO ABSORPTION VIA NASAL ROUTE AND DISTRIBUTION TO LUMBAR CSF IN HEALTHY NON-HUMAN PRIMATES (CYANOMOLGUS MONKEY).

LB-012 - ETHANOL AS AN EXCIPIENT IN DRUG FORMULATIONS ADMINISTERED TO NEONATES: PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING TO INFORM SAFETY.

LB-013 - PHYSIOLOGICALLY BASED ABSORPTION AND PHARMACOKINETIC MODEL FOR RIVOCERANIB AND ITS MAIN METABOLITE TO ASSESS POTENTIAL CYP3A4-MEDIATED DDI RISK.

LB-014 - POPULATION PHARMACOKINETIC ANALYSIS OF PHASE 1 SUBCUTANEOUS LEVOTHYROXINE FORMULATION (XP-8121).

PI-074 - A PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODEL EVALUATING THE DRUG-DRUG INTERACTION (DDI) POTENTIAL BETWEEN LAMOTRIGINE (LMT) AND ACETAMINOPHEN (APAP).

PI-076 - CANNABIDIOL EXPOSURES IN BREASTFED INFANTS COMPARED TO CHILDREN AS PREDICTED BY PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING.

PI-077 - DEVELOPMENT AND VERIFICATION OF A PYRIDOXIC ACID PBPK MODEL TO EVALUATE BIOMARKER INFORMED ORGANIC ANION TRANSPORTERS (OAT) 1 AND 3 INHIBITION.

PI-078 - LEVERAGING A DERMAL PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL OF A TOPICAL CREAM TO EXPLORE THE BIOEQUIVALENCE SAFE SPACE FOR INFLUENTIAL FORMULATION ATTRIBUTES.

PI-079 - LEVERAGING PBPK DDI APPLICATION TO ENLIGHTEN THE MECHANISMS OF THE INTERACTION BETWEEN PHENYTOIN AND OMEPRAZOLE AND POTENTIAL IMPACT IN EPILEPTIC PATIENTS.

PI-080 - LEVERAGING PBPK-BASED ANALYSIS TO SUPPORT AN ADAPTIVE TRIAL DESIGN IN CHILDREN.

PII-094 - 4Β-OH CHOLESTEROL AS ENDOGENOUS BIOMARKER FOR CYP3A4 INDUCER DDI STUDIES – A PBPK PLATFORM FOR IN SILICO COMPOUND TESTING.

PII-095 - APPLICATION OF A PERMEABILITY-LIMITED MULTI-COMPARTMENT LIVER MODEL TO INVESTIGATE RIFAMPICIN-MEDIATED ZONAL INDUCTION OF HEPATIC OATP1B1 IN A PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) FRAMEWORK.

PII-096 - MODEL INFORMED DRUG INTERACTION STUDY DESIGN FOR VESATOLIMOD AND CYP3A/P-GP MODULATORS USING PBPK.

PII-097 - PBPK MODELING OF LUNG TISSUE PREDICTS EFFICACY OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR WITH CONCOMITANT RIFABUTIN ADMINISTRATION.

PII-099 - PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL TO ASSESS THE DRUG-DRUG-GENE INTERACTION POTENTIAL OF BELZUTIFAN IN COMBINATION WITH CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN HEALTHY VOLUNTEERS.

PII-100 - POPULATION PHARMACOKINETIC ANALYSIS OF THE SUBLINGUAL FILM FORMULATION OF DEXMEDETOMIDINE (BXCL501) IN HEALTHY VOLUNTEERS AND ADULTS WITH SCHIZOPHRENIA OR BIPOLAR DISORDER.

PII-101 - PREDICTING CLINICAL EFFECTS OF CYP3A4 PERPETRATORS ON PIRTOBRUTINIB PHARMACOKINETICS USING PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELLING.

PII-102 - PREDICTION OF DRUG-DRUG INTERACTIONS (DDI) WITH A MODERATE CYP3A INDUCER: DEVELOPMENT AND VALIDATION OF PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL OF RIFABUTIN.

PII-103 - REGISTERED DIGOXIN DOSES FOR CHILDREN DO NOT LEAD TO OPTIMAL EXPOSURE: A PBPK STUDY.

PWI-001 - PBPK MODELING OF LUNG TISSUE PREDICTS EFFICACY OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR WITH CONCOMITANT RIFABUTIN ADMINISTRATION.

PWI-005 - APPLICATION OF A PERMEABILITY-LIMITED MULTI-COMPARTMENT LIVER MODEL TO INVESTIGATE RIFAMPICIN-MEDIATED ZONAL INDUCTION OF HEPATIC OATP1B1 IN A PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) FRAMEWORK.